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Alternatively activated dendritic cells derived from systemic lupus erythematosus patients  
have tolerogenic phenotype and function
HJ Wu1, Y Lo1, D Luk1, CS Lau1, LW Lu2, MY Mok1
1Division of Rheumatology and Clinical Immunology, Department of Medicine; 2Department of Pathology, The University of Hong 
Kong, Hong Kong
Background: Tolerogenic dendritic cells (DCs) are potential cell-based therapy in autoimmune diseases. 
Methods: In this study, we generated alternatively activated DCs (aaDCs) by treating monocyte-derived 
DCs from patients with systemic lupus erythematosus (SLE) and healthy subjects with combination of 1,25 
dihydroxyvitamin D(3) (vitD3) and dexamethasone followed by lipopolysaccharide-induced maturation. 
Results: Lupus aaDCs were found to acquire semi-mature phenotype that remained maturation-resistant 
to immunostimulants. They produced low level of interleukin-12 (IL-12) but high level of IL-10. They had 
attenuated allostimulatory effects on T cell activation and proliferation comparable to normal aaDCs and 
demonstrated differential immunomodulatory effects on naïve and memory T cells. These aaDCs were 
capable of inducing IL-10 producing regulatory T effectors from naïve T cells whereas they modulated cytokine 
profile with suppressed production of interferon-γ and IL-17 by co-cultured memory T cells with attenuated 
proliferation. 
Conclusions: These aaDCs were shown to be superior than those generated using vitD3 alone in lupus patients. 
Efficacy and tolerability of long-term tacrolimus treatment in lupus nephritis
DY Yap, MK Ma, MM Mok, GC Chan, LP Kwan, TM Chan
Department of Medicine, The University of Hong Kong, Hong Kong
introduction: Tacrolimus (TAC) is an emerging treatment for lupus nephritis (LN), but long-term data of this 
therapy are lacking.
Methods: We retrospectively reviewed 27 LN patients who received TAC treatment for 46.9±37.9 months.
Results: In 17 patients with class III/IV or V LN and persistent proteinuria of >2 g/day despite induction 
immunosuppression, add-on TAC treatment resulted in response rates of 66.7% and 80.0%, respectively. In 10 
patients with nephrotic syndrome due to class V LN, prednisolone and TAC as initial treatment was associated 
with response rates of 60.0% and 90.0% after 12 and 24 months, respectively. The overall proteinuria dropped 
from 3.6±2.6 g/d to 1.0±1.1 g/d (P<0.05). Four patients developed end-stage kidney disease, with 3-, 5-, and 
8-year renal survival rates of 93%, 83%, and 83%, respectively. In the remaining patients, serum creatinine and 
estimated glomerular filtration rate remained stable after 36 months. One patient with pre-existing chronic 
renal failure developed TAC nephrotoxicity. Four renal relapsed occurred, and all were associated with low 
TAC blood levels. Six (20.1%) patients had deterioration of hypertension and one (3.4%) patient had new-onset 
diabetes mellitus. Six (20.1%) patients had infections that required hospitalisation. Two patients succumbed, 
and was due to pneumonia and breast cancer respectively.
Conclusion: The results suggest efficacy of TAC in LN, especially in reducing proteinuria. Its role as long-term 
maintenance agent remains to be examined.
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